Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

SHE:300497 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	640.53	695.35	729.37	978.03	1,272	1,585
Trading Asset Securities	2.19	2.19	2.19	49.74	150.76	106.68
Cash & Short-Term Investments	642.71	697.54	731.56	1,028	1,423	1,692
Cash Growth	-4.15%	-4.65%	-28.82%	-27.79%	-15.88%	105.98%
Accounts Receivable	445.58	498.16	572.92	552.49	376.21	314.38
Other Receivables	46.33	53.85	128.31	78.21	80.01	57.44
Receivables	491.91	552.01	701.23	630.71	456.22	371.82
Inventory	444.53	421.05	434.68	553.69	416.15	287.98
Other Current Assets	16.34	10.42	9.97	17.11	15.97	14.98
Total Current Assets	1,595	1,681	1,877	2,229	2,312	2,367
Property, Plant & Equipment	2,287	2,267	2,331	2,201	1,857	1,199
Long-Term Investments	255.22	255.9	271.27	271.42	133.02	153.78
Goodwill	-	-	-	1.15	2.22	2.22
Other Intangible Assets	293.11	235	241.07	249.71	256.32	246.28
Long-Term Deferred Tax Assets	30.81	37.26	29.37	28.49	27.54	9.29
Long-Term Deferred Charges	-	-	-	-	-	2.2
Other Long-Term Assets	61.91	60.95	69.13	78.79	90.82	66.71
Total Assets	4,523	4,537	4,819	5,060	4,678	4,046
Accounts Payable	519.61	603.37	581.93	656.67	517.05	418.6
Accrued Expenses	13.47	44.05	44.52	42.4	51.97	37.75
Short-Term Debt	596.41	556.4	549.83	366.74	615.18	377.38
Current Portion of Long-Term Debt	416.78	311.78	78.78	7.96	33.5	-
Current Income Taxes Payable	6.79	0.05	0.82	8.71	13.89	42.11
Current Unearned Revenue	2.52	2.72	3.4	1.42	1.82	2.81
Other Current Liabilities	32.7	25.46	26.32	174.96	126.56	6.25
Total Current Liabilities	1,588	1,544	1,286	1,259	1,360	884.9
Long-Term Debt	631.48	736.48	998.26	1,043	353	65
Long-Term Unearned Revenue	103.03	77.67	62.39	62.03	50.3	43.73
Long-Term Deferred Tax Liabilities	1.93	1.96	2.05	6.27	3.92	4.3
Total Liabilities	2,325	2,360	2,348	2,370	1,767	997.93
Common Stock	550	550	550	550	550	550
Additional Paid-In Capital	1,381	1,381	1,414	1,408	1,406	1,465
Retained Earnings	411.02	408.78	680.88	881.68	1,023	1,084
Treasury Stock	-174.86	-174.86	-174.86	-174.86	-105.11	-100.02
Comprehensive Income & Other	15.66	15.45	14.3	16.89	6.08	8.34
Total Common Equity	2,183	2,180	2,485	2,681	2,880	3,007
Minority Interest	15.84	-3.54	-14.06	8.4	31.1	40.39
Shareholders' Equity	2,199	2,177	2,471	2,690	2,911	3,048
Total Liabilities & Equity	4,523	4,537	4,819	5,060	4,678	4,046
Total Debt	1,645	1,605	1,627	1,418	1,002	442.38
Net Cash (Debt)	-1,002	-907.13	-895.31	-389.97	421.54	1,249
Net Cash Growth	-	-	-	-	-66.26%	957.75%
Net Cash Per Share	-1.82	-1.70	-1.65	-0.72	0.78	2.70
Filing Date Shares Outstanding	538.65	538.65	538.65	538.65	538.65	540.73
Total Common Shares Outstanding	538.65	538.65	538.65	538.65	543.13	540.73
Working Capital	7.22	137.2	591.84	970.42	951.59	1,482
Book Value Per Share	4.05	4.05	4.61	4.98	5.30	5.56
Tangible Book Value	1,890	1,945	2,244	2,430	2,622	2,759
Tangible Book Value Per Share	3.51	3.61	4.17	4.51	4.83	5.10
Buildings	-	936.67	836.72	712.09	471.86	384.81
Machinery	-	1,641	1,423	1,232	851.39	621.88
Construction In Progress	-	457.86	695.78	736.4	922.19	494.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.